Humasis, 29.93% ↑ on Rising Theme of COVID-19 (Diagnosis/Treatment/Vaccine Development)

On the 22nd, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.07% compared to the previous day, showing strength, while Humasis, a related stock attracting attention, surged by 29.93% compared to the previous day. Humasis is known as an in vitro diagnostic device company.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Humasis’s quant financial score is 11.11 points, which is lower in stability, profitability, and growth scores compared to the average of other stocks related to COVID-19 (diagnosis/treatment/vaccine development, etc.). This can be interpreted as Humasis having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, United Pharmaceutical ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of analysis by the Robo Algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.